Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
NVS
Novartis AG
$121.68
Chart
$112.5 (+8.16%)
$103.85 (+17.17%)
$108.02 (+12.65%)
$106.13 (+14.65%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.84%
+1.11%
-0.22%
+0.32%
+28.68%
NVS
Novartis AG
Current Price
$121.68
Strong Buy
Login to view Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
Chart
$112.5 (+8.16%)
$103.85 (+17.17%)
$108.02 (+12.65%)
$106.13 (+14.65%)
NVS Latest Analysis
Novartis Gets Swiss Approval For First Malaria Drug For Babies. ) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved for .The new treatment also known as Riamet Baby in some countries was developed in collaboration with Medicines for Malaria Venture (MMV).Until now there has been no approved malaria treatment for infants weighing less than 4.5 kilograms. They have instead been treated with formulations intended for use in older children
Today
Novartis wins Swiss approval for Coartem Baby first malaria drug for infants and young children.
Today
Heres Why Novartis (NVS) is a Strong Momentum Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mon Jul 7, 2025
Novartis Cosentyx Fails Late-Stage Giant Cell Arteritis Trial. ) on Thursday released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing .Giant cell arteritis is an inflammation of the lining of the arteries. It often affects the arteries in the head especially .In the study Cosentyx was evaluated with a 26-week steroid taper and compared to a placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically signifi
Thu Jul 3, 2025
Paroxysmal Nocturnal Hemoglobinuria Market Set for Robust Growth During the Forecast Period (2025–2034) Owing to the Advancements in Complement Inhibitor Therapies | DelveInsight. Paroxysmal Nocturnal Hemoglobinuria Market Set for Robust Growth During the Forecast Period (2025–2034) Owing to the Advancements in Complement Inhibitor Therapies |. DelveInsight The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth driven by increasing disease awareness improved diagnostics a
Tue Jul 1, 2025
Novartis in deal with ProFound for cardiovascular disease therapies.
Thu Jun 26, 2025
Novartis: A SWAN Worth Owning.
Wed Jun 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings